Selinexor plus low-dose dexamethasone in chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (march): a phase ii, single-arm study

HIGHLIGHTS

• who: Lugui Qiu from the Laboratory of Experimental Hematology, Institute of Hematology and Peking Union Medical College, Tianjin, China have published the research work: Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study, in the Journal: (JOURNAL) of May/09,/2019
• what: The main reasons for that included disease progression (48.8%), patients` decision (24.4%), and adverse events (8.5%). It has been reported that the risk of lung infection in MM patients . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.